Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.
IOVA - Iovance Biotherapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$7.83
DETAILS
HIGH:
$13.00
LOW:
$5.00
MEDIAN:
$6.50
CONSENSUS:
$7.83
DOWNSIDE:
9.16%
Stock News
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 20, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 240,135 shares of Iovance's common stock to twenty new, non-executive employees.
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?
Shares of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) are trending Friday morning, continuing a momentum surge that recently pushed the biotech stock to a new 52-week high after gaining over 250% year-to-date.
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is trading at a 52-week high on Thursday, despite having no news to justify the move. Year to date, the stock has surged over 200%.
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy
Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates
Iovance Biotherapeutics, Inc. delivered a breakout Q2 '26 for Amtagvi sales, with management guiding for further growth ahead. IOVA's maturing clinical pipeline and imminent NSCLC readout position the company for further upside, given the market potential in NSCLC is several times larger than in melanoma. Potential competitor, IMTX, is expecting to produce results from a trial of its cell therapy, Anzu-cel, in melanoma in H1 '27.
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?
Iovance's revenue rose 66% last quarter due to strong demand for Amtagvi. The company also cut its losses by nearly 60%.
IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake
Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?
The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Iovance Biotherapeutics Q2 Earnings Call Highlights
Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic cancers.
Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due September
Iovance Biotherapeutics is rated a buy, driven by strong Q2 results, surging Amtagvi sales, and promising pipeline catalysts. Q2 product revenues reached $99M, 10% above management guidance, with gross margin at 56% and a net loss of $(47.3m), beating consensus. IOVA's pipeline includes frontline melanoma and NSCLC, with key data presentations at ESMO and a BLA submission for NSCLC planned next year.
Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago.
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter 2026 financial results, business achievements, and corporate updates.
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Thursday, August 6, 2026 at 8:30 a.m.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 16, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 139,930 shares of Iovance's common stock to seventeen new, non-executive employees.
Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness. Gross margin was impacted by temporary costs but is expected to improve to 50%+ as internal manufacturing scales and opex reductions take effect.
This Stock Is Up 74% This Year: Is It Too Late to Buy?
The biotech is clearly innovative, but sometimes that's not enough.
Price Targets
Iovance Biotherapeutics price target raised to $7 from $4 at UBS
$7.00
(was $7.99)
David Dai
·
UBS
Iovance Biotherapeutics price target raised to $11 from $10 at Mizuho
$11.00
(was $7.10)
Mizuho Securities
Iovance Biotherapeutics price target raised to $6 from $4 at Baird
$6.00
(was $6.21)
Collen Kusy
·
Robert W. Baird
Iovance Biotherapeutics price target raised to $13 from $11 at Barclays
$13.00
(was $6.21)
Barclays
Iovanace Biotherapeutics (IOVA) Reiterated at Market Outperform by Citizens
$5.00
(was $4.10)
Wells Fargo
Iovanace Biotherapeutics (IOVA) Reiterated at Market Outperform by Citizens
$5.00
(was $4.10)
National Bank
Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs
$2.00
(was $2.44)
Andrea Newkirk
·
Goldman Sachs
Iovance Biotherapeutics downgraded to Neutral from Buy at UBS
$2.00
(was $1.66)
David Dai
·
UBS
Iovance Biotherapeutics price target lowered to $6 from $7.50 at Piper Sandler
$6.00
(was $4.24)
Piper Sandler
Iovance Biotherapeutics price target lowered to $7.50 from $10 at Piper Sandler
$7.50
(was $5.85)
Joseph Catanzaro
·
Piper Sandler
UBS Starts Iovanace Biotherapeutics (IOVA) at Buy
$17.00
(was $9.82)
David Dai
·
UBS
Iovanace Biotherapeutics (IOVA) PT Lowered to $23 at Stifel
$23.00
(was $3.97)
Benjamin Burnett
·
Stifel Nicolaus
Iovanace Biotherapeutics (IOVA) PT Lowered to $24 at Baird
$24.00
(was $3.97)
Colleen Kusy
·
Robert W. Baird
Piper Sandler Downgrades Iovanace Biotherapeutics (IOVA) to Neutral
$10.00
(was $9.25)
Joseph Catanzaro
·
Piper Sandler
Iovance Biotherapeutics price target lowered to $23 from $25 at JMP Securities
$23.00
(was $4.00)
Reni Benjamin
·
JMP Securities
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
$28.00
(was $4.44)
Benjamin Burnett
·
Stifel Nicolaus
Iovanace Biotherapeutics (IOVA) PT Raised to $19 at Piper Sandler
$19.00
(was $14.21)
Joseph Catanzaro
·
Piper Sandler
Iovance Biotherapeutics downgraded to Neutral from Buy at Goldman Sachs
$6.00
(was $7.17)
Madhu Kumar
·
Goldman Sachs
Iovance Biotherapeutics price target lowered to $11 from $13 at Piper Sandler
$11.00
(was $6.62)
Joseph Catanzaro
·
Piper Sandler
Iovance Biotherapeutics (IOVA) Stock: $25 Target And Outperform Rating
$25.00
(was $5.75)
Michael Ulz
·
Robert W. Baird